What To Watch For. GSK said it would send its trial data to the FDA for regulatory approval. Big Number. 66,200. That’s the average number of endometrial cancer cases diagnosed in the U.S. each ...

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares ...

PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer ...

GSK Plc’s Jemperli helped extend the lives of patients with endometrial cancer in a late-stage test, suggesting the medicine could become the top seller the UK drugmaker is predicting.

The European Medicines Agency ((EMA)) accepted for review GSK's (GSK) application seeking approval of Jemperli to treat uterus cancer. Read more here ...

(RTTNews) - GlaxoSmithKline plc (GSK) Thursday said US Food and Drug Administration has approved Jemperli for endometrial cancer, based on the company's Biologics License Application.Jemperli is ...

GSK's potential cancer drug Jemperli cleared an important hurdle ahead of potentially receiving marketing permission from the European Medicines Agency. The British pharmaceutical giant said ...

GSK, which has sought to rebuild its oncology business in recent years, had been boosted by Jemperli's approval in the United States and UK to treat specific subtypes of advanced or recurrent ...

GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially receiving marketing permission from the European Medicines Agency. The British pharmaceutical giant said Monday that the ...